Japan Tobacco Cuts Its Pharmaceutical-related R&D Spending (Japan)
This article was originally published in PharmAsia News
Japan Tobacco (JT) cut its pharmaceutical-related research and development spending by nearly 50 percent between 2002 and 2006. JT spent 19.3 billion yen in pharmaceutical-related research and development for the fiscal year ending in March 2006. This is far below 34.5 billion yen spent for the year extending from March 2001 to March 2002. The Japanese government is considering a ban on all smoking in public places as a health measure. However, they have been lackluster in their anti-smoking campaign to date. JT is a private company that is 50 percent owned by Japan's Finance Ministry, and JT has a legal monopoly on tobacco manufacturing in Japan. (Click here for more
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.